Irritable bowel syndrome (IBS) is a gut–brain axis chronic disorder, characterized by recurrent abdominal pain and altered bowel habits in the absence of organic pathology. Nutrition plays a central role in symptom management, yet no single dietary strategy has demonstrated universal effectiveness. This narrative review critically evaluates current nutritional approaches to IBS. The low-Fermentable Oligo-, Di-, Mono-saccharides and Polyols (FODMAP) diet is the most extensively studied and provides short-term symptom relief, but its long-term effects on microbiota diversity remain concerning. The Mediterranean diet, due to its anti-inflammatory and prebiotic properties, offers a sustainable, microbiota-friendly option; however, it has specific limitations in the context of IBS, particularly due to the adverse effects of certain FODMAP-rich foods. A gluten-free diet may benefit individuals with suspected non-celiac gluten sensitivity, although improvements are often attributed to fructan restriction and placebo and nocebo effects. Lactose-free diets are effective in patients with documented lactose intolerance, while a high-soluble-fiber diet is beneficial for constipation-predominant IBS. IgG-based elimination diets are emerging but remain controversial and require further validation. In this review, we present the 10 dietary commandments for IBS, pragmatic and easily retained recommendations. It advocates a personalized, flexible, and multidisciplinary management approach, avoiding rigidity and standardized protocols, with the aim of optimizing adherence, symptom mitigation, and health-related quality of life. Future research should aim to evaluate, in real-world clinical settings, the impact and applicability of the 10 dietary commandments for IBS in terms of symptom improvement and quality of life
Some patients with eosinophilic esophagitis (EoE) remain symptomatic despite histological remission. In absence of strictures at endoscopy, empirical dilation has been suggested, however no data on usefulness are available. To investigate effectiveness of empirical dilation. Retrospective analysis of all EoE patients who achieved histological remission at our Institution between July 2018 and February 2024. Patients with persistent dysphagia and/or bolus impaction underwent dilation irrespective of stricture at endoscopy. Follow-up of ≥6 months was required. Forty-six patients (median age 42 years, 25 men) were included. Thirty-seven had no stricture and 9 had a stricture (i.e., S1 or R3 according to EREFS score). In the former group, 23/37 patients became asymptomatic whereas 14 were still symptomatic and underwent empirical dilation, clinically effective in 13 of them. A second dilation was needed in 2, after 25 and 31 months. In the latter group all patients underwent dilation and achieved clinical remission. All 45 patients remained in clinico-histological remission during a 14(8-46) months follow-up, with no change in medical treatment and a final I-SEE score of 1(0-1). Empirical esophageal dilation is highly effective when dysphagia/bolus impaction persists despite histological remission and should be considered before escalating treatment.
Irritable bowel syndrome (IBS) is a gut–brain interaction disorder often associated with food-related triggers, yet the efficacy of common exclusion diets remains debated. Confocal laser endomicroscopy (CLE) offers real-time, high-resolution imaging of intestinal mucosal changes, allowing the visualization of food-induced barrier dysfunction. Early evidence indicates that a substantial subset of IBS patients exhibit acute mucosal reactions to specific foods, identified as fluorescein leakage and cell shedding on CLE, with over 70% showing symptom improvements after tailored exclusion diets. These findings suggest that localized immune responses and barrier defects may contribute to IBS symptoms beyond IgE-driven immunologic mechanisms. However, most CLE-based studies are small, unblinded, and heterogeneous, limiting definitive conclusions. Further research is needed to validate the diagnostic accuracy of CLE, refine protocols, and clarify how best to integrate CLE into personalized dietary management for difficult-to-treat IBS.
Cannabinoid Hyperemesis Syndrome (CHS) is a severe condition associated with chronic cannabis use, characterized by cyclic vomiting, abdominal pain, and compulsive hot baths for symptom relief. We present the case of a 35‐year‐old male with at least a decade‐long history of cannabis use who presented with recurrent episodes of vomiting and dehydration. He experienced a potentially fatal episode of hypothermia and cardiac arrest after losing consciousness during a prolonged hot bath. Despite extensive diagnostic evaluations after many years, CHS was not identified until it was confirmed based on the Rome IV clinical criteria and elevated urinary cannabinoid levels (449 ng/mL). Management included rehydration, parenteral nutrition, and capsaicin cream targeting the transient receptor potential vanilloid Type 1 (TRPV1), as traditional antiemetics were ineffective, in conjunction with cannabis cessation. This case highlights the need for early recognition of CHS to prevent severe complications and avoid unnecessary diagnostic investigations. Prolonged cannabis abstinence remains the only definitive treatment, requiring a multidisciplinary approach. Increased awareness among clinicians is essential for timely diagnosis and appropriate management.
29 July 2026 in European Journal of Gastroenterology & Hepatology